RxDoctor Payments Data

Meghan Hermanson, MD

Ophthalmology · Cincinnati, OHNPI 1093246316

Payments from drug & device makers

$1,843in general payments, 2019–2025

Across 60 payments — averaging $30.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$786
  • AbbVie$272
  • Regeneron Healthcare Solutions, Inc.$221
  • Mallinckrodt Enterprises LLC$104
  • Sight Sciences, Inc.$87
  • Astellas Pharma US Inc$54
  • plus $319 from 11 others

What the payments were for

  • Food & beverage$1,843100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,843 in reported general payments places this provider in the 55th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$213,208
Medicare patients
1,041
Services billed
2,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine93$78,097
LumiganBimatoprost48$22,341
XiidraLifitegrast21$21,292
Cyclosporine19$14,905
RhopressaNetarsudil Mesylate22$11,566
Prednisolone Acetate251$9,041
CombiganBrimonidine Tartrate/Timolol12$6,022
Latanoprost656$4,763
MoxifloxacinMoxifloxacin Hcl153$4,401
Brimonidine Tartrate222$3,500
Ketorolac Tromethamine137$2,687
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat176$2,485
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$2,120
Travoprost13$1,848
Timolol Maleate168$1,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$272$106,460153 claims
Bausch & Lomb Americas Inc.Xiidra$16$21,29221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →